Truist lowered the firm's price target on Belden to $150 from $184 and keeps a Buy rating on the shares. The company delivered good Q1 results and Q2 guidance, but while the RUCKUS acquisition appears to be about 15% accretive to EPS, it raises questions about strategy and capital allocation, the analyst tells investors in a research note.
